LP-PLA2的原核表达、抗体制备及表位分析
|
摘要
脂蛋白相关磷脂酶A2(lipoprotein–associated phospholipase A2,LP-PLA2)属于VIIA型磷脂酶A2,它可以预测与冠脉事件有关的动脉粥样硬化和中风危险。目前,在国内,LP-PLA2临床诊断试剂主要依赖于从国外进口,所需费用昂贵,限制了该检测项目在我国的推广及应用,因此,研发LP-PLA2体外免疫诊断试剂尤为重要。
目的本研究旨在获取人脂蛋白相关磷脂酶A2蛋白,制备相应抗体,同时验证经生物信息学预测的表位肽的抗原性,为LP-PLA2体外免疫诊断试剂的研发奠定基础。
方法采用Trizol法从分化的THP-1细胞中提取总RNA,经RT-PCR扩增目的片段LP-PLA2;利用分子克隆技术构建原核表达质粒;转化入大肠杆菌BL21(DE3),优化诱导表达条件,进行多步骤纯化并除去标签,获得目的蛋白,免疫新西兰大白兔,制备抗LP-PLA2的多克隆抗体;运用多种生物信息学方法对LP-PLA2抗原表位进行预测,并用纯化的LP-PLA2多克隆抗体鉴定其抗原性。
结果
1.成功构建了PET-28a(+)-LP-PLA2,PGEX-4T-2-LP-PLA2,pCold TF-LP-PLA2等重组表达质粒。
2.经IPTG诱导表达后,SDS-PAGE电泳显示:LP-PLA2在PET-28a(+)-LP-PLA2表达载体中不表达;在PGEX-4T-2-LP-PLA2表达载体中少量表达,且主要以包涵体形式存在;在pCold TF-LP-PLA2表达载体中,获得表达量较高的融合蛋白,主要以上清形式存在。
3.将pCold TF-LP-PLA2诱导表达上清经镍柱亲和层析纯化后,获得TF-LP-PLA2重组蛋白,将该重组蛋白用HRV-3C prolease酶切后,用蓝胶分离纯化,获得了纯度约为90%、分子量约为45kD的蛋白,与预期相符,且该蛋白能够被市售的LP-PLA2多克隆抗体识别,证明获得了纯度较高的LP-PLA2目的蛋白。
4.制备了抗LP-PLA2的多克隆抗体,抗体效价>1:5.12×106 ,Western blot结果表明,该抗体特异性较高。
5.运用生物信息学软件综合分析预测了LP-PLA2的三段表位肽,体外抗原抗体免疫反应实验证实了三段表位肽均具有良好的抗原性。
结论成功表达并纯化获得了高纯度的LP-PLA2蛋白;制备了效价和纯度均较高的LP-PLA2多克隆抗体;运用生物信息学分析方法预测了LP-PLA2的三段表位肽,并证实了其具有良好的抗原性,可用于进一步制备多克隆和单克隆抗体。本研究为LP-PLA2体外诊断试剂的研发奠定了基础。
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a key enzyme as a risk predictor involved in atherosclerosis and ischemic stroke, and belongs to group VIIA of the phospholipase. At present, the clinical diagnostic reagents of LP-PLA2 mainly are dependent upon importation from foreign countries. Then the cost required is expensive, which is limited the application of LP-PLA2 in china. Therefore, it is important for us to development the immunoassays diagnostic reagents of LP-PLA2.
Objective The purpose of this study was to obtain human lipoprotein-associated phospholipase A2 protein and its antibody which was used to verify antigenic epitopes of LP-PLA2 predicted by bioinformatics. This study will afford a foundation for further establishing the immunoassays of LP-PLA2.
Methods Total RNA was isolated from differentiated THP-1 cells, and LP-PLA2 gene was amplified by RT-PCR. The PCR fragments were then cloned into expression vector, following by sequencing analysis. The positive recombinant plasmid was transformed into E.coli BL21(DE3) and the recombinant protein LP-PLA2 was expressed, Then the purified protein was identified by SDS-PAGE and Western blot. Rabbits were immunized with the LP-PLA2 protein and the polyclonal antibody was obtained. At the same time, predicted epitope of LP-PLA2 using variety of bioinformatics methods, and the antigenicity was identified with the LP-PLA polyclonal antibodies.
Results 1. LP-PLA2 gene was successfully cloned into Prokaryotic expression vector PET-28a(+)-LP-PLA2,PGEX-4T-2-LP-PLA2,and pCold TF-LP-PLA2.
2. After expression induced by IPTG, SDS-PAGE results showed that there was no LP-PLA2 protein expressed in the PET-28a(+)-LP-PLA and a small quantities of LP-PLA2 recombination protein were found expressed in the PGEX-4T-2-LP-PLA2 existing in the form of inclusion bodies. Besides there was LP-PLA2 recombination protein expressed in the pCold TF-LP-PLA2,existing as soluble protein of E. coli.
3. After LP-PLA2 expression supernatants were purified by Ni affinity chromatography and blue gel affinity chromatography respectively, the obtained LP-PLA2 protein which could reach a purity of about 90% was found to exist as a protein of molecular weight of about 45kD, and was identified by commercial polyclonal antibodies.
reach 1:5.12×106 by ELISA. Then the specificity was confirmed by Western blot.
5. Three epitope peptides of LP-PLA2 were predicted by bioinformatics software and were confirmed having good antigenicity by antigen-antibody immune response in vitro experiments. Conclusion The LP-PLA2 proteins and the specific polyclonal antibodies have been obtained. Three sections epitope peptides of LP-PLA2 were predicted by bioinformatics software and then confirmed of good antigenicity by antigen-antibody immune response in vitro experiments. What’s more these peptides could be used for further preparing polyclonal antibodies and monoclonal antibodies. Thus this study could afford a foundation for further establishing the immunoassays of LP-PLA2.
4. The polyclonal antibodies were obtained and titers examined could
目的本研究旨在获取人脂蛋白相关磷脂酶A2蛋白,制备相应抗体,同时验证经生物信息学预测的表位肽的抗原性,为LP-PLA2体外免疫诊断试剂的研发奠定基础。
方法采用Trizol法从分化的THP-1细胞中提取总RNA,经RT-PCR扩增目的片段LP-PLA2;利用分子克隆技术构建原核表达质粒;转化入大肠杆菌BL21(DE3),优化诱导表达条件,进行多步骤纯化并除去标签,获得目的蛋白,免疫新西兰大白兔,制备抗LP-PLA2的多克隆抗体;运用多种生物信息学方法对LP-PLA2抗原表位进行预测,并用纯化的LP-PLA2多克隆抗体鉴定其抗原性。
结果
1.成功构建了PET-28a(+)-LP-PLA2,PGEX-4T-2-LP-PLA2,pCold TF-LP-PLA2等重组表达质粒。
2.经IPTG诱导表达后,SDS-PAGE电泳显示:LP-PLA2在PET-28a(+)-LP-PLA2表达载体中不表达;在PGEX-4T-2-LP-PLA2表达载体中少量表达,且主要以包涵体形式存在;在pCold TF-LP-PLA2表达载体中,获得表达量较高的融合蛋白,主要以上清形式存在。
3.将pCold TF-LP-PLA2诱导表达上清经镍柱亲和层析纯化后,获得TF-LP-PLA2重组蛋白,将该重组蛋白用HRV-3C prolease酶切后,用蓝胶分离纯化,获得了纯度约为90%、分子量约为45kD的蛋白,与预期相符,且该蛋白能够被市售的LP-PLA2多克隆抗体识别,证明获得了纯度较高的LP-PLA2目的蛋白。
4.制备了抗LP-PLA2的多克隆抗体,抗体效价>1:5.12×106 ,Western blot结果表明,该抗体特异性较高。
5.运用生物信息学软件综合分析预测了LP-PLA2的三段表位肽,体外抗原抗体免疫反应实验证实了三段表位肽均具有良好的抗原性。
结论成功表达并纯化获得了高纯度的LP-PLA2蛋白;制备了效价和纯度均较高的LP-PLA2多克隆抗体;运用生物信息学分析方法预测了LP-PLA2的三段表位肽,并证实了其具有良好的抗原性,可用于进一步制备多克隆和单克隆抗体。本研究为LP-PLA2体外诊断试剂的研发奠定了基础。
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a key enzyme as a risk predictor involved in atherosclerosis and ischemic stroke, and belongs to group VIIA of the phospholipase. At present, the clinical diagnostic reagents of LP-PLA2 mainly are dependent upon importation from foreign countries. Then the cost required is expensive, which is limited the application of LP-PLA2 in china. Therefore, it is important for us to development the immunoassays diagnostic reagents of LP-PLA2.
Objective The purpose of this study was to obtain human lipoprotein-associated phospholipase A2 protein and its antibody which was used to verify antigenic epitopes of LP-PLA2 predicted by bioinformatics. This study will afford a foundation for further establishing the immunoassays of LP-PLA2.
Methods Total RNA was isolated from differentiated THP-1 cells, and LP-PLA2 gene was amplified by RT-PCR. The PCR fragments were then cloned into expression vector, following by sequencing analysis. The positive recombinant plasmid was transformed into E.coli BL21(DE3) and the recombinant protein LP-PLA2 was expressed, Then the purified protein was identified by SDS-PAGE and Western blot. Rabbits were immunized with the LP-PLA2 protein and the polyclonal antibody was obtained. At the same time, predicted epitope of LP-PLA2 using variety of bioinformatics methods, and the antigenicity was identified with the LP-PLA polyclonal antibodies.
Results 1. LP-PLA2 gene was successfully cloned into Prokaryotic expression vector PET-28a(+)-LP-PLA2,PGEX-4T-2-LP-PLA2,and pCold TF-LP-PLA2.
2. After expression induced by IPTG, SDS-PAGE results showed that there was no LP-PLA2 protein expressed in the PET-28a(+)-LP-PLA and a small quantities of LP-PLA2 recombination protein were found expressed in the PGEX-4T-2-LP-PLA2 existing in the form of inclusion bodies. Besides there was LP-PLA2 recombination protein expressed in the pCold TF-LP-PLA2,existing as soluble protein of E. coli.
3. After LP-PLA2 expression supernatants were purified by Ni affinity chromatography and blue gel affinity chromatography respectively, the obtained LP-PLA2 protein which could reach a purity of about 90% was found to exist as a protein of molecular weight of about 45kD, and was identified by commercial polyclonal antibodies.
reach 1:5.12×106 by ELISA. Then the specificity was confirmed by Western blot.
5. Three epitope peptides of LP-PLA2 were predicted by bioinformatics software and were confirmed having good antigenicity by antigen-antibody immune response in vitro experiments. Conclusion The LP-PLA2 proteins and the specific polyclonal antibodies have been obtained. Three sections epitope peptides of LP-PLA2 were predicted by bioinformatics software and then confirmed of good antigenicity by antigen-antibody immune response in vitro experiments. What’s more these peptides could be used for further preparing polyclonal antibodies and monoclonal antibodies. Thus this study could afford a foundation for further establishing the immunoassays of LP-PLA2.
4. The polyclonal antibodies were obtained and titers examined could
引文
[1] World Health Organization. Prevention of cardiovascular disease. Pocket Guidelines for Assessment and Management of Cardiovascular Risk[S]. Geneva, 2007.
[2] Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma[J]. Biochim Biophys Acta, 2009, 1791(5):327-338.
[3] Tjoelker LW,Wilder C,Eberhardt C etal:Anti-inflammatory properties of a plateletactivating factor acetylhydrolase[J]. Nature .1995,374:549-553.
[4] Tew DG, Southan C, Rice SQ etal. Purification,properties,sequencing,and cloning of a lipoprotein-associated,serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins[J]. Arterioscler. Thromb. Vasc.Biol, 1996,16:591-599.
[5] Muzammil Ali,Mohammadd Madjid.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target[J].Future Cardiol,2009,5(2):159-173.
[6] Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk[J]. Prog Cardiovasc Nurs,2009, 24(4):181-9.
[7] Lerman A, McConnell J P. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor[J]. The American Journal of Cardiology. 2008, 101(12A): 11F–22F.
[8] Krishnankutty Sudhir. Clinical review: Lipoprotein-Associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease [J].J Clin Endocrinol Metab, 2005, 90(5):3100–3105.
[1] Bhatti S,Hakeem A,Cilingiroglu M.Lp-PLA(2) as a marker of cardiovascular diseases[J]. Curr Atheroscler Rep. 2010 ,12(2):140-144.
[2] Lynne T. Braun & Michael H. Davidson. Lp-PLA2: A New Target for Statin Therapy[J]. Curr Atheroscler Rep 2010,12:29–33.
[3] Fu-jun ZHANG, Mao-jun CAI, Jing-kang SHEN, etal.Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis1[J].Acta Pharmacologica Sinica :2006, 27 (6): 679–684.
[4] Wang WY, Li J, Yang D,et al.OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways[J]. Cardiovasc Res. 2010,85(4):845-52.
[5] D.G. Tew, C. Southan, S.Q.J. Rice, et al., Purification, properties,sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins[J]. Arterioscler. Thromb. Vasc. Biol. 1996,16:591–599.
[6] Fujun Zhang , Li Dong , Maojun Cai, etal.Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems[J]. Protein Expression and Purification.2006,48: 300–306.
[7] Susanne Gr?slund, P?r Nordlund, Johan Weigelt,et al. Protein production and purification.Nature methods[J].2008,5(2):135-146.
[1] Ario de Marco. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli[J]. Microbial Cell Factories. 2009, 8-26.
[2]邹颖,毕新岭,顾军等.血小板活化因子乙酰水解酶融合蛋白的表达﹑纯化及鉴定[J].第二军医大学学报,2007:28(5):504-507.
[3] Fujun Zhang, Li Dong, Maojun Cai, etal.Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems [J].Protein Expression and Purification.2006,48:300–306.
[4] Kandror O, Goldberg AL. Trigger factor is induced upon cold shock and enhances viability of Escherichia coli at low temperatures[J]. Proc Natl Acad Sci USA. 1997,94(10):4978-81.
[5] Gupta R, Lakshmipathy SK, Chang HC, et al. Trigger factor lacking the PPIase domain can enhance the folding of eukaryotic multi-domain proteins in Escherichia coli[J]. FEBS Lett. 2010,584(16):3620-3624.
[6] Walker PA, Leong LEC, Ng PWP etal.Efficient and rapid affinity purification of proteins using recombinant fusion proteases[J]. Biotechnology .1994,12: 601–605.
[7] Lawrence S.Cousens , Oakland , Calif.etal. Platelet-activating factor acetylhydrolast(PAF-AH) therapeutic uses:United States, 6,099,836[P]. 2000-8-8.
[1]吕素芳,刘峥,郭广君等.大肠杆菌中表达外源重组蛋白的研究[J].科学技术与工程,2006,6(18):2872-2876.
[2]张竹君,周玉,李鹏等,一个新的高保守自身免疫反应相关分子IRF-4结合蛋白多克隆抗体制备[J].第三军医大学学报:2008,30(13):1242-1245.
[3] Yuan Xin Hu,Ju Yuan Guo,Lu Shen,etal.Get effective polyclonal antisera in one month[J].Cell Research,2002,12(2):157-160.
[4] Harlow.E,Lane,D.Using Antibodies:A Laboratory Manual[M].沈关心,龚非力等译.北京:科学出版社,2002.
[1]周光炎.免疫学原理[M].上海科技出版社,2000:36-37.
[2]王艳华,张德林,殷宏等.抗原表位预测方法的研究进展[J].中国兽医科学.2009,39(10):938-940.
[3] BARLOW D J,EDWARDS M S,THORNTON J M.Continuous and discontinuous protein antigenic determinants[J].Nature,1986,322(6081):747.
[4] Xingdong Yang and Xinglong Yu. An introduction to epitope prediction methods and software[J].Reviews in medical virology.2009,19:77-96.
[5] Kyte J,DolittleR F.A Simple method for displaying hydropathiccharacter of a protein[J].J Mol Biol 1983,157(1):105.
[6] Gershoni JM ,Stem B,Venisova G.Combinatorial libraries, epitope structureand the prediction of conformations[J].Immunol Today 1997,18(5):108.
[7] Tsche H,Modern methods in protein and nucleic acid research [M].1th,New York:Walter de Gruger Berlin 1990,1231.
[8] Karplus PA,SchultzG E.Prediction of chain flexibility in proteins [J].Immunology 1985,72(2):212.
[9] Welling GW,weijer WJ,Vander Z R,et a1.Prediction of sequential antigenic regions in proteins[J].FEBS Lett 1985.188 (2):215.
[10]来鲁华.蛋白质的结构预测与分子设计[M].第1版.北京:北京大学出版社,1993,49.
[11]梁秀丽,方丽云,王东方,等.猪细小病毒HN-3株VP2基因克隆与抗原性分析[J].河南农业科学,2007,11:100-103.
[12]李秋霞,滕达,童德文等.非洲猪瘟病毒VP73基因主要抗原表位区的融合原核表达[J].中国生物工程杂志.2010,30(2)60-65.
[1] Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age[J]. Nat Clin Pract Cardiovasc Med. 2005, 2(1):29–36.
[2] Cook NR, Buring JE, Ridker PM. The effect of including C reactive protein in cardiovascular risk prediction models for women[J].Ann Intern Med. 2006,145:21–29.
[3] Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention[J]. Am J Cardiol. 2008, 101(Suppl):23F–33F.
[4] Lynne T. Braun & Michael H. Davidson,Lp-PLA2: A New Target for Statin Therapy[J]. Curr Atheroscler Rep. 2010, 12:29-33.
[5] Tjoelker LW,Wilder C,Eberhardt C etal:Anti-inflammatory properties of a plateletactivating factor acetylhydrolase[J].Nature . 1995,374:549-553.
[6] Tew DG, Southan C, Rice SQ etal.:Purification,properties,sequencing,and cloning of a lipoprotein-associated,serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins[J]. Arterioscler.Thromb. Vasc.Biol. 1996,16:591-599.
[7] Schaloske RH,Dennis EA: The phospholipase A2 superfamily and its group numbering system.Biochim.Biophys[J].Acta. 2006,1761:1246-1259.
[8] TselepisAD,JohnChapmanM.inflammation,bioactivelipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activatingfactor-acetylhydrolase[J]. Atheroscler. 2002,3:57-68.
[9] Stafforini DM,Elstad MR,Mcintyre TM,Zimmerman GA,Prescott SM:Human macrophages secret platelet-activating factor acetylhydrolase[J]. J Biol Chem. 1990,265:9682-9687.
[10] Muzammil Ali,Mohammadd Madjid:Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target[J].Future Cardiol. 2009,5(2):159-173.
[11] Turunen p,puhakka H,Rutanen J etal.:Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta[J].Atherosclerosis .179,27-33(2005).
[12] Liodra J,Angeli V,Liu J,Trogan E,Fisher EA,Randolph GJ:Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive,but not progressive,plaques[J].Proc Natl Acad. 2004,101:11779-11784.
[13] Arakawa H,Qian JY,Baatar D etal.:local expression of platelet-activating factor acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation,shear stress-induced thrombosis,and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits[J].Circulation. 2005,111:3302-3309.
[14] Marathe GK,Zimmerman GA,McIntyreTM:Platelet-activating factor acetylhydrolase, and not paraoxonase-1,is the oxidized phospholipids hydrolase of high density lipoprotein particles[J]. J Biol Chem. 2003, 278:3937-3947.
[15] Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase)and cardiovascular disease[J]. Curr Opin Lipidol. 2003,14:347-352.
[16] Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated A2 as a cardiovascular risk marker[J]. Am J Cardiol .2008,101(Suppl):41F–50F.
[17] Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor [J]. Am J Cardiol .2008:101 (Suppl):11F–22F.
[18] Shi Y,Zhang P,Zhang L ,etal. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses[J].Atherosclerosis. 2007, 191:54-62.
[19] HakkinenT, Luoma JS, Hiltunen MO, et al. Lipoprotein-AssociatedPhospholipaseA2 , Platelet-Activating Factor Acetylhydrolase,Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions[J]. Arterioscler. Thromb.Vasc.Biol. 1999,19:2909-2917.
[20] Kolodgie FD, Burke AP,Skorija KS etal.:Lipoprotein-associated phospholipase A2 protein expression in the natural progression of huaman coronary atherosclerosis[J]. Arterioscler. Thromb. Vasc. Biol. 2006,26:2523 -2529 .
[21] Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target[J]. Arterioscler.Thromb.Vasc.Biol. 2005,25:923-931.
[22] Carpenter KL, Challis IR, Arends MJ.Mildly oxidized LDL induces more macrophage death than moderately oxidized LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPAR gamma[J]. FEBS lett. 2003,553:145-150.
[23] Ballantyne CM, Hoogeveen RC,Bang H. etal.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study[J].Circulation. 2004,109:837-842.
[24] Winkler K,Winkelmann BR,Scharnagl H etal.Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health study[J].Circulation. 2005,111:980-987.
[25] DavidsonMH, CorsonMA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J]. Am J Cardiol. 2008,101(Suppl):51F–57F.
[26] Asztalos BF,Le Maulf F,Dallal GE,etal.Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins[J].Am.J.Cardiol. 2007,99:681-685.
[27] Mohler ER ,Ballantyne CM,Davidson MH etal.The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with s coronary heart disease or coronary heart disease risk equivalent:the results of a multicenter, randomized, double-blind, placebo-controlled study[J].JAM.Coll.Cardiol.2008,51:1632-1641.
[28] Manolio T. Novel risk markers and clinical practice[J]. N Engl J Med. 2003,349(17):1587–1589.
[29] Hoogeveen RC, Ballantyne CM. PLACTM test for identification of individuals at increased risk for coronary heart disease[J]. Expert Rev Mol Diagn. 2005, 5:9–14.
[30] Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein- associated phospholipase A2: a review and recommendation of a clinical cut point for adults[J]. Prev Cardiol. 2006,9:138-143.
[31] Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J]. Am J Cardiol. 2008,101(suppl): 51F–57F.
[32] Nagel G, Rapp K, Wabitsch M, et al. Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany[J]. Clin Chem. 2008,54(2):317–325.
[33] Engler MM, Engler MB, Boghosian CL, et al. Effect of a low fat diet, antioxidant vitamins, docosahexaenoic acid and a cocoa beverage on lipoprotein- associated phospholipase (Lp-PLA2) in hyperlipidemic children. Abstract presented at the 3rd International Symposium Integrated Biomarkers in Cardiovascular Diseases, Seattle, WA, July 2008.
[34] Iribarren C,Gross MD,Darinian JA,Jacobs DRJr,Sidney S,Loria CM:Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults:the CARDIA study.Arterioscler[J].Thromb.Vasc.Biol. 2005,25:216-221.
[35] Koenig W,Twardella D,Breenner H,Rothenbacher D:lipoprotein- associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J]. Arterioscler Thromb Vasc Biol. 2006,26:1586-1593.
[36] O’Donoghue M,Morrow DA,Sabatine MS etal. lipoprotein- associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVEIT-TIMI22 (Pravastation or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)trial[J].Circulation. 2006,13:1745-1752.
[37] Gazi I,Lourida ES,Filippatos T, etal. lipoprotein- associated phospholipase A2activity is a marker of small,dense LDL particles in human plasma.Clin.Chem2005,51:2264-2273.
[2] Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma[J]. Biochim Biophys Acta, 2009, 1791(5):327-338.
[3] Tjoelker LW,Wilder C,Eberhardt C etal:Anti-inflammatory properties of a plateletactivating factor acetylhydrolase[J]. Nature .1995,374:549-553.
[4] Tew DG, Southan C, Rice SQ etal. Purification,properties,sequencing,and cloning of a lipoprotein-associated,serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins[J]. Arterioscler. Thromb. Vasc.Biol, 1996,16:591-599.
[5] Muzammil Ali,Mohammadd Madjid.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target[J].Future Cardiol,2009,5(2):159-173.
[6] Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk[J]. Prog Cardiovasc Nurs,2009, 24(4):181-9.
[7] Lerman A, McConnell J P. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor[J]. The American Journal of Cardiology. 2008, 101(12A): 11F–22F.
[8] Krishnankutty Sudhir. Clinical review: Lipoprotein-Associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease [J].J Clin Endocrinol Metab, 2005, 90(5):3100–3105.
[1] Bhatti S,Hakeem A,Cilingiroglu M.Lp-PLA(2) as a marker of cardiovascular diseases[J]. Curr Atheroscler Rep. 2010 ,12(2):140-144.
[2] Lynne T. Braun & Michael H. Davidson. Lp-PLA2: A New Target for Statin Therapy[J]. Curr Atheroscler Rep 2010,12:29–33.
[3] Fu-jun ZHANG, Mao-jun CAI, Jing-kang SHEN, etal.Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis1[J].Acta Pharmacologica Sinica :2006, 27 (6): 679–684.
[4] Wang WY, Li J, Yang D,et al.OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways[J]. Cardiovasc Res. 2010,85(4):845-52.
[5] D.G. Tew, C. Southan, S.Q.J. Rice, et al., Purification, properties,sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins[J]. Arterioscler. Thromb. Vasc. Biol. 1996,16:591–599.
[6] Fujun Zhang , Li Dong , Maojun Cai, etal.Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems[J]. Protein Expression and Purification.2006,48: 300–306.
[7] Susanne Gr?slund, P?r Nordlund, Johan Weigelt,et al. Protein production and purification.Nature methods[J].2008,5(2):135-146.
[1] Ario de Marco. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli[J]. Microbial Cell Factories. 2009, 8-26.
[2]邹颖,毕新岭,顾军等.血小板活化因子乙酰水解酶融合蛋白的表达﹑纯化及鉴定[J].第二军医大学学报,2007:28(5):504-507.
[3] Fujun Zhang, Li Dong, Maojun Cai, etal.Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems [J].Protein Expression and Purification.2006,48:300–306.
[4] Kandror O, Goldberg AL. Trigger factor is induced upon cold shock and enhances viability of Escherichia coli at low temperatures[J]. Proc Natl Acad Sci USA. 1997,94(10):4978-81.
[5] Gupta R, Lakshmipathy SK, Chang HC, et al. Trigger factor lacking the PPIase domain can enhance the folding of eukaryotic multi-domain proteins in Escherichia coli[J]. FEBS Lett. 2010,584(16):3620-3624.
[6] Walker PA, Leong LEC, Ng PWP etal.Efficient and rapid affinity purification of proteins using recombinant fusion proteases[J]. Biotechnology .1994,12: 601–605.
[7] Lawrence S.Cousens , Oakland , Calif.etal. Platelet-activating factor acetylhydrolast(PAF-AH) therapeutic uses:United States, 6,099,836[P]. 2000-8-8.
[1]吕素芳,刘峥,郭广君等.大肠杆菌中表达外源重组蛋白的研究[J].科学技术与工程,2006,6(18):2872-2876.
[2]张竹君,周玉,李鹏等,一个新的高保守自身免疫反应相关分子IRF-4结合蛋白多克隆抗体制备[J].第三军医大学学报:2008,30(13):1242-1245.
[3] Yuan Xin Hu,Ju Yuan Guo,Lu Shen,etal.Get effective polyclonal antisera in one month[J].Cell Research,2002,12(2):157-160.
[4] Harlow.E,Lane,D.Using Antibodies:A Laboratory Manual[M].沈关心,龚非力等译.北京:科学出版社,2002.
[1]周光炎.免疫学原理[M].上海科技出版社,2000:36-37.
[2]王艳华,张德林,殷宏等.抗原表位预测方法的研究进展[J].中国兽医科学.2009,39(10):938-940.
[3] BARLOW D J,EDWARDS M S,THORNTON J M.Continuous and discontinuous protein antigenic determinants[J].Nature,1986,322(6081):747.
[4] Xingdong Yang and Xinglong Yu. An introduction to epitope prediction methods and software[J].Reviews in medical virology.2009,19:77-96.
[5] Kyte J,DolittleR F.A Simple method for displaying hydropathiccharacter of a protein[J].J Mol Biol 1983,157(1):105.
[6] Gershoni JM ,Stem B,Venisova G.Combinatorial libraries, epitope structureand the prediction of conformations[J].Immunol Today 1997,18(5):108.
[7] Tsche H,Modern methods in protein and nucleic acid research [M].1th,New York:Walter de Gruger Berlin 1990,1231.
[8] Karplus PA,SchultzG E.Prediction of chain flexibility in proteins [J].Immunology 1985,72(2):212.
[9] Welling GW,weijer WJ,Vander Z R,et a1.Prediction of sequential antigenic regions in proteins[J].FEBS Lett 1985.188 (2):215.
[10]来鲁华.蛋白质的结构预测与分子设计[M].第1版.北京:北京大学出版社,1993,49.
[11]梁秀丽,方丽云,王东方,等.猪细小病毒HN-3株VP2基因克隆与抗原性分析[J].河南农业科学,2007,11:100-103.
[12]李秋霞,滕达,童德文等.非洲猪瘟病毒VP73基因主要抗原表位区的融合原核表达[J].中国生物工程杂志.2010,30(2)60-65.
[1] Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age[J]. Nat Clin Pract Cardiovasc Med. 2005, 2(1):29–36.
[2] Cook NR, Buring JE, Ridker PM. The effect of including C reactive protein in cardiovascular risk prediction models for women[J].Ann Intern Med. 2006,145:21–29.
[3] Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention[J]. Am J Cardiol. 2008, 101(Suppl):23F–33F.
[4] Lynne T. Braun & Michael H. Davidson,Lp-PLA2: A New Target for Statin Therapy[J]. Curr Atheroscler Rep. 2010, 12:29-33.
[5] Tjoelker LW,Wilder C,Eberhardt C etal:Anti-inflammatory properties of a plateletactivating factor acetylhydrolase[J].Nature . 1995,374:549-553.
[6] Tew DG, Southan C, Rice SQ etal.:Purification,properties,sequencing,and cloning of a lipoprotein-associated,serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins[J]. Arterioscler.Thromb. Vasc.Biol. 1996,16:591-599.
[7] Schaloske RH,Dennis EA: The phospholipase A2 superfamily and its group numbering system.Biochim.Biophys[J].Acta. 2006,1761:1246-1259.
[8] TselepisAD,JohnChapmanM.inflammation,bioactivelipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activatingfactor-acetylhydrolase[J]. Atheroscler. 2002,3:57-68.
[9] Stafforini DM,Elstad MR,Mcintyre TM,Zimmerman GA,Prescott SM:Human macrophages secret platelet-activating factor acetylhydrolase[J]. J Biol Chem. 1990,265:9682-9687.
[10] Muzammil Ali,Mohammadd Madjid:Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target[J].Future Cardiol. 2009,5(2):159-173.
[11] Turunen p,puhakka H,Rutanen J etal.:Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta[J].Atherosclerosis .179,27-33(2005).
[12] Liodra J,Angeli V,Liu J,Trogan E,Fisher EA,Randolph GJ:Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive,but not progressive,plaques[J].Proc Natl Acad. 2004,101:11779-11784.
[13] Arakawa H,Qian JY,Baatar D etal.:local expression of platelet-activating factor acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation,shear stress-induced thrombosis,and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits[J].Circulation. 2005,111:3302-3309.
[14] Marathe GK,Zimmerman GA,McIntyreTM:Platelet-activating factor acetylhydrolase, and not paraoxonase-1,is the oxidized phospholipids hydrolase of high density lipoprotein particles[J]. J Biol Chem. 2003, 278:3937-3947.
[15] Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase)and cardiovascular disease[J]. Curr Opin Lipidol. 2003,14:347-352.
[16] Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated A2 as a cardiovascular risk marker[J]. Am J Cardiol .2008,101(Suppl):41F–50F.
[17] Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor [J]. Am J Cardiol .2008:101 (Suppl):11F–22F.
[18] Shi Y,Zhang P,Zhang L ,etal. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses[J].Atherosclerosis. 2007, 191:54-62.
[19] HakkinenT, Luoma JS, Hiltunen MO, et al. Lipoprotein-AssociatedPhospholipaseA2 , Platelet-Activating Factor Acetylhydrolase,Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions[J]. Arterioscler. Thromb.Vasc.Biol. 1999,19:2909-2917.
[20] Kolodgie FD, Burke AP,Skorija KS etal.:Lipoprotein-associated phospholipase A2 protein expression in the natural progression of huaman coronary atherosclerosis[J]. Arterioscler. Thromb. Vasc. Biol. 2006,26:2523 -2529 .
[21] Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target[J]. Arterioscler.Thromb.Vasc.Biol. 2005,25:923-931.
[22] Carpenter KL, Challis IR, Arends MJ.Mildly oxidized LDL induces more macrophage death than moderately oxidized LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPAR gamma[J]. FEBS lett. 2003,553:145-150.
[23] Ballantyne CM, Hoogeveen RC,Bang H. etal.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study[J].Circulation. 2004,109:837-842.
[24] Winkler K,Winkelmann BR,Scharnagl H etal.Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health study[J].Circulation. 2005,111:980-987.
[25] DavidsonMH, CorsonMA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J]. Am J Cardiol. 2008,101(Suppl):51F–57F.
[26] Asztalos BF,Le Maulf F,Dallal GE,etal.Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins[J].Am.J.Cardiol. 2007,99:681-685.
[27] Mohler ER ,Ballantyne CM,Davidson MH etal.The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with s coronary heart disease or coronary heart disease risk equivalent:the results of a multicenter, randomized, double-blind, placebo-controlled study[J].JAM.Coll.Cardiol.2008,51:1632-1641.
[28] Manolio T. Novel risk markers and clinical practice[J]. N Engl J Med. 2003,349(17):1587–1589.
[29] Hoogeveen RC, Ballantyne CM. PLACTM test for identification of individuals at increased risk for coronary heart disease[J]. Expert Rev Mol Diagn. 2005, 5:9–14.
[30] Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein- associated phospholipase A2: a review and recommendation of a clinical cut point for adults[J]. Prev Cardiol. 2006,9:138-143.
[31] Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J]. Am J Cardiol. 2008,101(suppl): 51F–57F.
[32] Nagel G, Rapp K, Wabitsch M, et al. Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany[J]. Clin Chem. 2008,54(2):317–325.
[33] Engler MM, Engler MB, Boghosian CL, et al. Effect of a low fat diet, antioxidant vitamins, docosahexaenoic acid and a cocoa beverage on lipoprotein- associated phospholipase (Lp-PLA2) in hyperlipidemic children. Abstract presented at the 3rd International Symposium Integrated Biomarkers in Cardiovascular Diseases, Seattle, WA, July 2008.
[34] Iribarren C,Gross MD,Darinian JA,Jacobs DRJr,Sidney S,Loria CM:Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults:the CARDIA study.Arterioscler[J].Thromb.Vasc.Biol. 2005,25:216-221.
[35] Koenig W,Twardella D,Breenner H,Rothenbacher D:lipoprotein- associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J]. Arterioscler Thromb Vasc Biol. 2006,26:1586-1593.
[36] O’Donoghue M,Morrow DA,Sabatine MS etal. lipoprotein- associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVEIT-TIMI22 (Pravastation or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)trial[J].Circulation. 2006,13:1745-1752.
[37] Gazi I,Lourida ES,Filippatos T, etal. lipoprotein- associated phospholipase A2activity is a marker of small,dense LDL particles in human plasma.Clin.Chem2005,51:2264-2273.